Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP13 | P45452 | 16/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6208308 | 0.91 | MMP13 (0.59) | MMP13PDE10ASCN9A | |
| SCHEMBL6208246 | 0.87 | MMP13 (0.59) | MMP13SCN9A | |
| SCHEMBL6208373 | 0.86 | MMP13 (0.61) | MMP13PDE10A | |
| SCHEMBL6207854 | 0.85 | MMP13 (0.58) | MMP13SCN9AHRH3 | |
| SCHEMBL6208731 | 0.85 | MMP13 (0.61) | MMP13 | |
| SCHEMBL6208480 | 0.85 | MMP13 (0.75) | MMP13 | |
| SCHEMBL6208702 | 0.85 | MMP13 (0.61) | MMP13 | |
| SCHEMBL6209115 | 0.85 | MMP13 (0.62) | MMP13MCHR1 | |
| SCHEMBL6209142 | 0.84 | MMP13 (0.56) | MMP13SCN9AHRH3 | |
| SCHEMBL6210184 | 0.83 | MMP13 (0.58) | MMP13HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1501833-B1 | N-SUBSTITUTED-HETEROARYLOXY-ARYL-SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PROD INC (US) | 2005-11-02 | — | — | EP | claimed |
| US-6900201-B2 | N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. (US) | 2005-05-31 | — | — | US | claimed |
| EP-1501833-B1 | N-SUBSTITUTED-HETEROARYLOXY-ARYL-SPIRO-PYRIMIDINE-2,4,6-TRIONE METALLOPROTEINASE INHIBITORS | PFIZER PROD INC (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6900201-B2 | N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. (US) | 2005-05-31 | — | — | US | disclosed |
| US-20040010141-A1 | N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | PFIZER INC. | 2004-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040010141-A1 | N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors | MMP9, MMP8, MMP2 | MMP13 14/4885PDE10A 2610/4885SCN9A 3935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.